logo-loader
AIM:SUMM

Summit Therapeutics PLC

Receive alerts
Market:
AIM
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Summit Therapeutics is a leader in antibiotic innovation. Summit’s new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.

Deep dive We explore the investor case for growth companies

Snapshot

  • Developing new-mechanism antibiotics
  • Lead drug targets C.difficile
  • Phase III studies already underway
  • Well-funded thanks to biotech billionaire Bob Duggan's investment of US$50mln in December